Treatment and survival of patients harboring histological variants of glioblastoma

Alicia Ortega, Miriam Nuño, Sartaaj Walia, Debraj Mukherjee, Keith L. Black, Chirag G. Patil

Research output: Contribution to journalArticle

Abstract

It is unclear whether the survival difference observed between glioblastoma (GBM), giant cell glioblastoma (gcGBM), and gliosarcoma (GSM) patients is due to differences in tumor histology, patient demographics, and/or treatment regimens. The USA National Cancer Database was utilized to evaluate patients diagnosed with GBM, gcGBM, and GSM between 1998 and 2011. Kaplan-Meier survival estimates and Cox proportional hazards models were utilized to estimate overall survival. A cohort of 69,935 patients was analyzed; 67,509 (96.5%) of these patients had GBM, 592 (0.9%) gcGBM, and 1834 (2.6%) GSM. The median age for GBM and GSM patients was 61 versus 56 years for gcGBM (p < 0.0001). Higher extent of resection (p < 0.0001) and radiation (p = 0.001) were observed in gcGBM patients compared to other histologies. Multivariate analysis showed that gcGBM patients had a 20% reduction in the hazards of mortality (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.69-0.93) compared to GBM, while GSM patients trended towards higher hazards of mortality (HR 1.04, 95% CI 0.96-1.12) than the GBM cohort. Previous studies have suggested a disparity in the survival of patients with GBM tumors and their histological variants. Using a large cohort of patients treated at hospitals nationwide, this study found a 20% reduction in the hazards of mortality in gcGBM patients compared to GBM. Similarly, gcGBM patients had a 24% reduction in the hazards of mortality compared to the GSM cohort. GSM patients had a 3% increase in the hazards of mortality compared to GBM.

Original languageEnglish (US)
Pages (from-to)1709-1713
Number of pages5
JournalJournal of Clinical Neuroscience
Volume21
Issue number10
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Glioblastoma
Gliosarcoma
Survival
Therapeutics
Mortality
Histology
Confidence Intervals
Neoplasms
Kaplan-Meier Estimate
Proportional Hazards Models

Keywords

  • Chemotherapy
  • Giant cell glioblastoma
  • Glioblastoma
  • Gliosarcoma
  • Overall survival

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Physiology (medical)
  • Medicine(all)

Cite this

Treatment and survival of patients harboring histological variants of glioblastoma. / Ortega, Alicia; Nuño, Miriam; Walia, Sartaaj; Mukherjee, Debraj; Black, Keith L.; Patil, Chirag G.

In: Journal of Clinical Neuroscience, Vol. 21, No. 10, 01.01.2014, p. 1709-1713.

Research output: Contribution to journalArticle

Ortega, Alicia ; Nuño, Miriam ; Walia, Sartaaj ; Mukherjee, Debraj ; Black, Keith L. ; Patil, Chirag G. / Treatment and survival of patients harboring histological variants of glioblastoma. In: Journal of Clinical Neuroscience. 2014 ; Vol. 21, No. 10. pp. 1709-1713.
@article{a505f8cfe618436285f952e822e7de0a,
title = "Treatment and survival of patients harboring histological variants of glioblastoma",
abstract = "It is unclear whether the survival difference observed between glioblastoma (GBM), giant cell glioblastoma (gcGBM), and gliosarcoma (GSM) patients is due to differences in tumor histology, patient demographics, and/or treatment regimens. The USA National Cancer Database was utilized to evaluate patients diagnosed with GBM, gcGBM, and GSM between 1998 and 2011. Kaplan-Meier survival estimates and Cox proportional hazards models were utilized to estimate overall survival. A cohort of 69,935 patients was analyzed; 67,509 (96.5{\%}) of these patients had GBM, 592 (0.9{\%}) gcGBM, and 1834 (2.6{\%}) GSM. The median age for GBM and GSM patients was 61 versus 56 years for gcGBM (p < 0.0001). Higher extent of resection (p < 0.0001) and radiation (p = 0.001) were observed in gcGBM patients compared to other histologies. Multivariate analysis showed that gcGBM patients had a 20{\%} reduction in the hazards of mortality (hazard ratio [HR] 0.80, 95{\%} confidence interval [CI] 0.69-0.93) compared to GBM, while GSM patients trended towards higher hazards of mortality (HR 1.04, 95{\%} CI 0.96-1.12) than the GBM cohort. Previous studies have suggested a disparity in the survival of patients with GBM tumors and their histological variants. Using a large cohort of patients treated at hospitals nationwide, this study found a 20{\%} reduction in the hazards of mortality in gcGBM patients compared to GBM. Similarly, gcGBM patients had a 24{\%} reduction in the hazards of mortality compared to the GSM cohort. GSM patients had a 3{\%} increase in the hazards of mortality compared to GBM.",
keywords = "Chemotherapy, Giant cell glioblastoma, Glioblastoma, Gliosarcoma, Overall survival",
author = "Alicia Ortega and Miriam Nu{\~n}o and Sartaaj Walia and Debraj Mukherjee and Black, {Keith L.} and Patil, {Chirag G.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.jocn.2014.05.003",
language = "English (US)",
volume = "21",
pages = "1709--1713",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",
number = "10",

}

TY - JOUR

T1 - Treatment and survival of patients harboring histological variants of glioblastoma

AU - Ortega, Alicia

AU - Nuño, Miriam

AU - Walia, Sartaaj

AU - Mukherjee, Debraj

AU - Black, Keith L.

AU - Patil, Chirag G.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - It is unclear whether the survival difference observed between glioblastoma (GBM), giant cell glioblastoma (gcGBM), and gliosarcoma (GSM) patients is due to differences in tumor histology, patient demographics, and/or treatment regimens. The USA National Cancer Database was utilized to evaluate patients diagnosed with GBM, gcGBM, and GSM between 1998 and 2011. Kaplan-Meier survival estimates and Cox proportional hazards models were utilized to estimate overall survival. A cohort of 69,935 patients was analyzed; 67,509 (96.5%) of these patients had GBM, 592 (0.9%) gcGBM, and 1834 (2.6%) GSM. The median age for GBM and GSM patients was 61 versus 56 years for gcGBM (p < 0.0001). Higher extent of resection (p < 0.0001) and radiation (p = 0.001) were observed in gcGBM patients compared to other histologies. Multivariate analysis showed that gcGBM patients had a 20% reduction in the hazards of mortality (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.69-0.93) compared to GBM, while GSM patients trended towards higher hazards of mortality (HR 1.04, 95% CI 0.96-1.12) than the GBM cohort. Previous studies have suggested a disparity in the survival of patients with GBM tumors and their histological variants. Using a large cohort of patients treated at hospitals nationwide, this study found a 20% reduction in the hazards of mortality in gcGBM patients compared to GBM. Similarly, gcGBM patients had a 24% reduction in the hazards of mortality compared to the GSM cohort. GSM patients had a 3% increase in the hazards of mortality compared to GBM.

AB - It is unclear whether the survival difference observed between glioblastoma (GBM), giant cell glioblastoma (gcGBM), and gliosarcoma (GSM) patients is due to differences in tumor histology, patient demographics, and/or treatment regimens. The USA National Cancer Database was utilized to evaluate patients diagnosed with GBM, gcGBM, and GSM between 1998 and 2011. Kaplan-Meier survival estimates and Cox proportional hazards models were utilized to estimate overall survival. A cohort of 69,935 patients was analyzed; 67,509 (96.5%) of these patients had GBM, 592 (0.9%) gcGBM, and 1834 (2.6%) GSM. The median age for GBM and GSM patients was 61 versus 56 years for gcGBM (p < 0.0001). Higher extent of resection (p < 0.0001) and radiation (p = 0.001) were observed in gcGBM patients compared to other histologies. Multivariate analysis showed that gcGBM patients had a 20% reduction in the hazards of mortality (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.69-0.93) compared to GBM, while GSM patients trended towards higher hazards of mortality (HR 1.04, 95% CI 0.96-1.12) than the GBM cohort. Previous studies have suggested a disparity in the survival of patients with GBM tumors and their histological variants. Using a large cohort of patients treated at hospitals nationwide, this study found a 20% reduction in the hazards of mortality in gcGBM patients compared to GBM. Similarly, gcGBM patients had a 24% reduction in the hazards of mortality compared to the GSM cohort. GSM patients had a 3% increase in the hazards of mortality compared to GBM.

KW - Chemotherapy

KW - Giant cell glioblastoma

KW - Glioblastoma

KW - Gliosarcoma

KW - Overall survival

UR - http://www.scopus.com/inward/record.url?scp=84908499578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908499578&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2014.05.003

DO - 10.1016/j.jocn.2014.05.003

M3 - Article

C2 - 24980627

AN - SCOPUS:84908499578

VL - 21

SP - 1709

EP - 1713

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

IS - 10

ER -